Phase 3 Trial Update: Elacestrant + Everolimus Study Recruiting (Aug 2026)

A Phase 3 clinical trial update was recorded on August 20, 2026, for the study titled "Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i," registered as NCT06382948. The trial's current status is listed as recruiting. This study is evaluating elacestrant in combination with everolimus in patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer whose disease has progressed following endocrine therapy and CDK4/6 inhibitor treatment. No results have been posted for this trial as of this update. The event data does not include information on patient outcomes, safety findings, or efficacy signals. This brief reflects only the recruitment status and trial design details as registered. Readers interested in the study can consult the official clinicaltrials.gov listing for eligibility criteria, enrollment details, and future updates as the trial progresses. This update pertains to a trial involving elacestrant and everolimus and does not directly concern gonadorelin, though it is being reported within a broader peptide and compound news context. For background on gonadorelin, readers can refer to the compound overview.